000137681 001__ 137681
000137681 005__ 20240229112521.0
000137681 0247_ $$2doi$$a10.1002/ijc.31900
000137681 0247_ $$2pmid$$apmid:30259989
000137681 0247_ $$2ISSN$$a0020-7136
000137681 0247_ $$2ISSN$$a1097-0215
000137681 0247_ $$2altmetric$$aaltmetric:48972004
000137681 037__ $$aDKFZ-2018-01558
000137681 041__ $$aeng
000137681 082__ $$a610
000137681 1001_ $$aHonda, K.$$b0
000137681 245__ $$aCA19-9 and Apolipoprotein-A2 isoforms as detection markers for pancreatic cancer - a prospective evaluation.
000137681 260__ $$aBognor Regis$$bWiley-Liss$$c2019
000137681 3367_ $$2DRIVER$$aarticle
000137681 3367_ $$2DataCite$$aOutput Types/Journal article
000137681 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1551707643_21937
000137681 3367_ $$2BibTeX$$aARTICLE
000137681 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000137681 3367_ $$00$$2EndNote$$aJournal Article
000137681 520__ $$aRecently, we identified unique processing patterns of apolipoprotein A2 (ApoA2) in patients with pancreatic cancer. This study provides a first prospective evaluation of an ApoA2 isoform ('ApoA2-ATQ/AT'), alone and in combination with carbohydrate antigen 19-9 (CA19-9), as an early detection biomarker for pancreatic cancer. We performed ELISA measurements of CA19-9 and ApoA2-ATQ/AT in 156 patients with pancreatic cancer and 217 matched controls within the European EPIC cohort, using plasma samples collected up to 60 months prior to diagnosis. The detection discrimination statistics were calculated for risk scores by strata of lag-time. For CA19-9, in univariate marker analyses, C-statistics to distinguish future pancreatic cancer patients from cancer-free individuals were 0.80 for plasma taken ≤6 months before diagnosis, and 0.71 for >6-18 months; for ApoA2-ATQ/AT, C-statistics were 0.62, and 0.65, respectively. Joint models based on ApoA2-ATQ/AT plus CA19-9 significantly improved discrimination within >6-18 months (C = 0.74 vs. 0.71 for CA19-9 alone, p = 0.022) and ≤18 months (C = 0.75 vs. 0.74, p = 0.022). At 98% specificity, and for lag times of ≤6, >6-18 or ≤18 months, sensitivities were 57%, 36% and 43% for CA19-9 combined with ApoA2-ATQ/AT, respectively, vs. 50%, 29% and 36% for CA19-9 alone. Compared to CA19-9 alone, the combination of CA19-9 and ApoA2-ATQ/AT may improve detection of pancreatic cancer up to 18 months prior to diagnosis under usual care, and may provide a useful first measure for pancreatic cancer detection prior to imaging. This article is protected by copyright. All rights reserved.
000137681 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000137681 588__ $$aDataset connected to CrossRef, PubMed,
000137681 7001_ $$0P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aKatzke, Verena$$b1
000137681 7001_ $$0P:(DE-He78)6519c85d61a3def7974665471b8a4f74$$aHüsing, A.$$b2$$udkfz
000137681 7001_ $$aOkaya, S.$$b3
000137681 7001_ $$aShoji, H.$$b4
000137681 7001_ $$aOnidani, K.$$b5
000137681 7001_ $$aOlsen, A.$$b6
000137681 7001_ $$aTjønneland, A.$$b7
000137681 7001_ $$aOvervad, K.$$b8
000137681 7001_ $$aWeiderpass, E.$$b9
000137681 7001_ $$aVineis, P.$$b10
000137681 7001_ $$aMuller, D.$$b11
000137681 7001_ $$aTsilidis, K. K.$$b12
000137681 7001_ $$00000-0002-5558-2437$$aPalli, D.$$b13
000137681 7001_ $$aPala, V.$$b14
000137681 7001_ $$aTumino, R.$$b15
000137681 7001_ $$aNaccarati, A.$$b16
000137681 7001_ $$aPanico, S.$$b17
000137681 7001_ $$aAleksandrova, K.$$b18
000137681 7001_ $$aBoeing, H.$$b19
000137681 7001_ $$aBueno-de-Mesquita, H. B.$$b20
000137681 7001_ $$aPeeters, P. H.$$b21
000137681 7001_ $$aTrichopoulou, A.$$b22
000137681 7001_ $$aLagiou, P.$$b23
000137681 7001_ $$aKhaw, K-T$$b24
000137681 7001_ $$aWareham, N. J.$$b25
000137681 7001_ $$aTravis, R. C.$$b26
000137681 7001_ $$aMerino, S.$$b27
000137681 7001_ $$00000-0001-5256-0163$$aDuell, E. J.$$b28
000137681 7001_ $$aRodríguez-Barranco, M.$$b29
000137681 7001_ $$aChirlaque, M. D.$$b30
000137681 7001_ $$aBarricarte, A.$$b31
000137681 7001_ $$aRebours, V.$$b32
000137681 7001_ $$aBoutron-Ruault, M-C$$b33
000137681 7001_ $$aRomana Mancini, F.$$b34
000137681 7001_ $$aBrennan, P.$$b35
000137681 7001_ $$aScelo, G.$$b36
000137681 7001_ $$aManjer, J.$$b37
000137681 7001_ $$aSund, M.$$b38
000137681 7001_ $$aÖhlund, D.$$b39
000137681 7001_ $$0P:(DE-He78)5323704270b6393dcea70186ffd86bca$$aCanzian, Federico$$b40
000137681 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b41$$eLast author
000137681 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.31900$$n8$$p1877-1887$$tInternational journal of cancer$$v144$$x0020-7136$$y2019
000137681 909CO $$ooai:inrepo02.dkfz.de:137681$$pVDB
000137681 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000137681 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000137681 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000137681 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000137681 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2015
000137681 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000137681 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000137681 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000137681 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000137681 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000137681 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000137681 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2015
000137681 9141_ $$y2019
000137681 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000137681 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6519c85d61a3def7974665471b8a4f74$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000137681 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5323704270b6393dcea70186ffd86bca$$aDeutsches Krebsforschungszentrum$$b40$$kDKFZ
000137681 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b41$$kDKFZ
000137681 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000137681 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebserkrankungen$$x0
000137681 9201_ $$0I:(DE-He78)C055-20160331$$kC055$$lGenomische Epidemiologie$$x1
000137681 980__ $$ajournal
000137681 980__ $$aVDB
000137681 980__ $$aI:(DE-He78)C020-20160331
000137681 980__ $$aI:(DE-He78)C055-20160331
000137681 980__ $$aUNRESTRICTED